Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Isolated Fracture of the Medial CuneiformA Case Report.

Babu NS, Gambardella GV, Bowlby MA.

J Am Podiatr Med Assoc. 2017 Sep;107(5):436-439. doi: 10.7547/16-013.

PMID:
29077495
2.

Combined Total Ankle Arthroplasty With Posterior Tibial Tendon Transfer for End-Stage Cavovarus Deformity.

Schuberth JM, Bowlby MA, Christensen JC.

J Foot Ankle Surg. 2016 Jul-Aug;55(4):885-90. doi: 10.1053/j.jfas.2016.02.006. Epub 2016 Apr 16.

PMID:
27095088
3.

Qualification of fMRI as a biomarker for pain in anesthetized rats by comparison with behavioral response in conscious rats.

Zhao F, Williams M, Bowlby M, Houghton A, Hargreaves R, Evelhoch J, Williams DS.

Neuroimage. 2014 Jan 1;84:724-32. doi: 10.1016/j.neuroimage.2013.09.036. Epub 2013 Sep 21.

PMID:
24064074
4.

Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats.

Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JI, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowlby MR, Kuduk SD, Coleman PJ, Hargreaves R, Winrow CJ, Renger JJ.

Neuropsychopharmacology. 2013 Nov;38(12):2401-8. doi: 10.1038/npp.2013.139. Epub 2013 May 31.

5.

Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition.

Uslaner JM, Tye SJ, Eddins DM, Wang X, Fox SV, Savitz AT, Binns J, Cannon CE, Garson SL, Yao L, Hodgson R, Stevens J, Bowlby MR, Tannenbaum PL, Brunner J, Mcdonald TP, Gotter AL, Kuduk SD, Coleman PJ, Winrow CJ, Renger JJ.

Sci Transl Med. 2013 Apr 3;5(179):179ra44. doi: 10.1126/scitranslmed.3005213.

6.

2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.

Zhou D, Gross JL, Adedoyin AB, Aschmies SB, Brennan J, Bowlby M, Di L, Kubek K, Platt BJ, Wang Z, Zhang G, Brandon N, Comery TA, Robichaud AJ.

J Med Chem. 2012 Mar 8;55(5):2452-68. doi: 10.1021/jm300011d. Epub 2012 Feb 28.

PMID:
22313242
7.

Pyrrolidin-3-yl-N-methylbenzamides as potent histamine 3 receptor antagonists.

Zhou D, Gross JL, Sze JY, Adedoyin AB, Bowlby M, Di L, Platt BJ, Zhang G, Brandon N, Comery TA, Robichaud AJ.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5957-60. doi: 10.1016/j.bmcl.2011.07.061. Epub 2011 Jul 27.

PMID:
21843941
8.

Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research.

Leiser SC, Dunlop J, Bowlby MR, Devilbiss DM.

Biochem Pharmacol. 2011 Jun 15;81(12):1408-21. doi: 10.1016/j.bcp.2010.10.002. Epub 2010 Oct 19. Review.

PMID:
20937262
9.

Ion channel screening plates: design, construction, and maintenance.

Mayer SC, Butera JA, Diller DJ, Dunlop J, Ellingboe J, Fan KY, Kaftan E, Mekonnen B, Mobilio D, Paslay J, Tawa G, Vasilyev D, Bowlby MR.

Assay Drug Dev Technol. 2010 Aug;8(4):504-11. doi: 10.1089/adt.2009.0239.

PMID:
20470241
10.

Genetic and functional analysis of human P2X5 reveals a distinct pattern of exon 10 polymorphism with predominant expression of the nonfunctional receptor isoform.

Kotnis S, Bingham B, Vasilyev DV, Miller SW, Bai Y, Yeola S, Chanda PK, Bowlby MR, Kaftan EJ, Samad TA, Whiteside GT.

Mol Pharmacol. 2010 Jun;77(6):953-60. doi: 10.1124/mol.110.063636. Epub 2010 Mar 11.

PMID:
20223879
11.

A novel high-throughput screening assay for HCN channel blocker using membrane potential-sensitive dye and FLIPR.

Vasilyev DV, Shan QJ, Lee YT, Soloveva V, Nawoschik SP, Kaftan EJ, Dunlop J, Mayer SC, Bowlby MR.

J Biomol Screen. 2009 Oct;14(9):1119-28. doi: 10.1177/1087057109345526. Epub 2009 Sep 22.

PMID:
19773585
12.

Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and pain.

Dunlop J, Vasilyev D, Lu P, Cummons T, Bowlby MR.

Curr Pharm Des. 2009;15(15):1767-72. Review.

PMID:
19442189
13.

A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits.

Leiser SC, Bowlby MR, Comery TA, Dunlop J.

Pharmacol Ther. 2009 Jun;122(3):302-11. doi: 10.1016/j.pharmthera.2009.03.009. Epub 2009 Apr 5. Review.

PMID:
19351547
14.

The role of calsenilin/DREAM/KChIP3 in contextual fear conditioning.

Alexander JC, McDermott CM, Tunur T, Rands V, Stelly C, Karhson D, Bowlby MR, An WF, Sweatt JD, Schrader LA.

Learn Mem. 2009 Feb 17;16(3):167-77. doi: 10.1101/lm.1261709. Print 2009 Mar.

15.

Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide).

Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, Jow F, Kramer A, Bowlby MR, Randall A, Kowal D, Gilbert A, Comery TA, Larocque J, Soloveva V, Brown J, Roncarati R.

J Pharmacol Exp Ther. 2009 Mar;328(3):766-76. doi: 10.1124/jpet.108.146514. Epub 2008 Dec 2.

PMID:
19050173
16.

Characterization of compounds on nicotinic acetylcholine receptor alpha7 channels using higher throughput electrophysiology.

Friis S, Mathes C, Sunesen M, Bowlby MR, Dunlop J.

J Neurosci Methods. 2009 Feb 15;177(1):142-8. doi: 10.1016/j.jneumeth.2008.10.007. Epub 2008 Oct 19.

PMID:
19000713
17.

hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk.

Bowlby MR, Peri R, Zhang H, Dunlop J.

Curr Drug Metab. 2008 Nov;9(9):965-70. Review.

PMID:
18991593
18.

Ion channel screening.

Dunlop J, Bowlby M, Peri R, Tawa G, LaRocque J, Soloveva V, Morin J.

Comb Chem High Throughput Screen. 2008 Aug;11(7):514-22. Review.

PMID:
18694388
19.
20.

Amiloride is neuroprotective in an MPTP model of Parkinson's disease.

Arias RL, Sung ML, Vasylyev D, Zhang MY, Albinson K, Kubek K, Kagan N, Beyer C, Lin Q, Dwyer JM, Zaleska MM, Bowlby MR, Dunlop J, Monaghan M.

Neurobiol Dis. 2008 Sep;31(3):334-41. doi: 10.1016/j.nbd.2008.05.008. Epub 2008 Jul 7.

PMID:
18606547
21.

Functional screening of α7 nicotinic receptor ligands.

Dunlop J, Peri R, Terstappen GC, Bowlby M.

Expert Opin Drug Discov. 2008 Jun;3(6):623-8. doi: 10.1517/17460441.3.6.623.

PMID:
23506144
22.

Hyperpolarization-activated cyclic nucleotide-gated channel mRNA and protein expression in large versus small diameter dorsal root ganglion neurons: correlation with hyperpolarization-activated current gating.

Kouranova EV, Strassle BW, Ring RH, Bowlby MR, Vasilyev DV.

Neuroscience. 2008 Jun 2;153(4):1008-19. doi: 10.1016/j.neuroscience.2008.03.032. Epub 2008 Mar 22.

PMID:
18450385
23.

High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology.

Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R.

Nat Rev Drug Discov. 2008 Apr;7(4):358-68. doi: 10.1038/nrd2552. Review.

PMID:
18356919
24.

Disruption of Kv1.1 N-type inactivation by novel small molecule inhibitors (disinactivators).

Lu Q, Peevey J, Jow F, Monaghan MM, Mendoza G, Zhang H, Wu J, Kim CY, Bicksler J, Greenblatt L, Lin SS, Childers W, Bowlby MR.

Bioorg Med Chem. 2008 Mar 15;16(6):3067-75. doi: 10.1016/j.bmc.2007.12.031. Epub 2007 Dec 23.

PMID:
18226531
25.

Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities.

Ruan B, Pong K, Jow F, Bowlby M, Crozier RA, Liu D, Liang S, Chen Y, Mercado ML, Feng X, Bennett F, von Schack D, McDonald L, Zaleska MM, Wood A, Reinhart PH, Magolda RL, Skotnicki J, Pangalos MN, Koehn FE, Carter GT, Abou-Gharbia M, Graziani EI.

Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):33-8. Epub 2007 Dec 27.

26.

Novel pharmacological activity of loperamide and CP-339,818 on human HCN channels characterized with an automated electrophysiology assay.

Lee YT, Vasilyev DV, Shan QJ, Dunlop J, Mayer S, Bowlby MR.

Eur J Pharmacol. 2008 Feb 26;581(1-2):97-104. Epub 2007 Dec 4.

PMID:
18162181
27.

Validation of a medium-throughput electrophysiological assay for KCNQ2/3 channel enhancers using IonWorks HT.

Jow F, Shen R, Chanda P, Tseng E, Zhang H, Kennedy J, Dunlop J, Bowlby MR.

J Biomol Screen. 2007 Dec;12(8):1059-67.

PMID:
18087070
28.

In vitro screening strategies for nicotinic receptor ligands.

Dunlop J, Roncarati R, Jow B, Bothmann H, Lock T, Kowal D, Bowlby M, Terstappen GC.

Biochem Pharmacol. 2007 Oct 15;74(8):1172-81. Epub 2007 Jul 10.

PMID:
17706607
29.

Direct inhibition of Ih by analgesic loperamide in rat DRG neurons.

Vasilyev DV, Shan Q, Lee Y, Mayer SC, Bowlby MR, Strassle BW, Kaftan EJ, Rogers KE, Dunlop J.

J Neurophysiol. 2007 May;97(5):3713-21. Epub 2007 Mar 28.

30.

The effect of mGlu5 receptor positive allosteric modulators on signaling molecules in brain slices.

Liu F, Zhang G, Hornby G, Vasylyev D, Bowlby M, Park K, Gilbert A, Marquis K, Andree TH.

Eur J Pharmacol. 2006 May 1;536(3):262-8. Epub 2006 Apr 5.

PMID:
16600209
31.

A novel method for patch-clamp automation.

Vasilyev D, Merrill T, Iwanow A, Dunlop J, Bowlby M.

Pflugers Arch. 2006 May;452(2):240-7. Epub 2006 Apr 5.

PMID:
16596408
32.

Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE.

Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5161-6. Epub 2006 Mar 20.

33.

Validation of DRG-like F11 cells for evaluation of KCNQ/M-channel modulators.

Jow F, He L, Kramer A, Hinson J, Bowlby MR, Dunlop J, Wang K.

Assay Drug Dev Technol. 2006 Feb;4(1):49-56.

PMID:
16506888
34.

Development of a novel automated ion channel recording method using "inside-out" whole-cell membranes.

Vasilyev DV, Merrill TL, Bowlby MR.

J Biomol Screen. 2005 Dec;10(8):806-13. Epub 2005 Oct 18.

PMID:
16234349
35.

Identification and characterization of small molecule modulators of KChIP/Kv4 function.

Bowlby MR, Chanda P, Edris W, Hinson J, Jow F, Katz AH, Kennedy J, Krishnamurthy G, Pitts K, Ryan K, Zhang H, Greenblatt L.

Bioorg Med Chem. 2005 Nov 15;13(22):6112-9. Epub 2005 Aug 2.

PMID:
16081294
36.
38.

Two N-terminal domains of Kv4 K(+) channels regulate binding to and modulation by KChIP1.

Scannevin RH, Wang K, Jow F, Megules J, Kopsco DC, Edris W, Carroll KC, Lü Q, Xu W, Xu Z, Katz AH, Olland S, Lin L, Taylor M, Stahl M, Malakian K, Somers W, Mosyak L, Bowlby MR, Chanda P, Rhodes KJ.

Neuron. 2004 Feb 19;41(4):587-98.

39.

Dietary counselling for dyslipidemia in primary care: results of a randomized trial.

Reid R, Fodor G, Lydon-Hassen K, D'Angelo MS, McCrea J, Bowlby M, Difrancesco L.

Can J Diet Pract Res. 2002 Winter;63(4):169-75.

PMID:
12493139
40.

Remodelling inactivation gating of Kv4 channels by KChIP1, a small-molecular-weight calcium-binding protein.

Beck EJ, Bowlby M, An WF, Rhodes KJ, Covarrubias M.

J Physiol. 2002 Feb 1;538(Pt 3):691-706.

41.

Modulation of A-type potassium channels by a family of calcium sensors.

An WF, Bowlby MR, Betty M, Cao J, Ling HP, Mendoza G, Hinson JW, Mattsson KI, Strassle BW, Trimmer JS, Rhodes KJ.

Nature. 2000 Feb 3;403(6769):553-6.

PMID:
10676964
42.
43.

Modulation of the Kv1.3 potassium channel by receptor tyrosine kinases.

Bowlby MR, Fadool DA, Holmes TC, Levitan IB.

J Gen Physiol. 1997 Nov;110(5):601-10.

44.

Kinetic variability and modulation of dSlo, a cloned calcium-dependent potassium channel.

Bowlby MR, Levitan IB.

Neuropharmacology. 1996;35(7):867-75.

PMID:
8938717
45.
46.
47.
48.

Ultrastructure and Neuronal Control of Luminous Cells in the Copepod Gaussia princeps.

Bowlby MR, Case JF.

Biol Bull. 1991 Jun;180(3):440-446. doi: 10.2307/1542344.

PMID:
29304651
49.

Patterns of Stimulated Bioluminescence in Two Pyrosomes (Tunicata: Pyrosomatidae).

Bowlby MR, Widder EA, Case JF.

Biol Bull. 1990 Dec;179(3):340-350. doi: 10.2307/1542326.

PMID:
29314963
50.

VARIABILITY IN FLASH CHARACTERISTICS OF A BIOLUMINESCENT COPEPOD.

Latz MI, Frank TM, Bowlby MR, Widder EA, Case JF.

Biol Bull. 1987 Dec;173(3):489-503. doi: 10.2307/1541695.

PMID:
29320222

Supplemental Content

Loading ...
Support Center